Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 33-40 , April 2004

Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes

Received 28 February 2003 ,Revised 11 August 2003 ,Accepted 1 October 2003.

References 

  1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diab. Care 23 (2001) S4–S19.
  2. Polonsky KS, Given BD, Hirsch LJ, et al.  Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1988;318:1231–1239
  3. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diab. Med. 1996;13:S159–S165
  4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837–853.
  5. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 2002;41:471–483
  6. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with Type 2 diabetes. Diab. Care. 2000;23:518–523
  7. Fuhlendorff J, Rorsman P, Kofod H, et al.  Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47:345–351
  8. Goldberg RB, Einhorn D, Luca CP, Rendell MS, Damsbo P, Huang W-C, et al. A randomized placebo-controlled trial of repaglinide in the treatment of Type 2 diabetes. Diab. Care. 1998;21:1897–1903
  9. Jovanovic L, Dailey G, Huang W-C, Strange P, Goldstein BJ. Repaglinide in Type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J. Clin. Pharmacol. 2000;40:49–57
  10. Van Gaal LF, Van Acker KL, de Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naı̈ve Type 2 diabetes. Diab. Res. Clin. Pract. 2001;53:141–148
  11. Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int. J. Obes. 2000;24:S38–S44
  12. Moses RG, Gomis R, Frandsen KB, Schlienger J-L, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycaemic control in therapy-naı̈ve Type 2 diabetes. Diab. Care. 2001;24:11–15
  13. Kristensen JS, Frandsen KB, Bayen T, Miller PG. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia. 1999;42:A4
  14. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. For the Scandinavian Repaglinide Group: comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetes Med. 2001;18:395–401
  15. Schmitz O, Lund S, Andersen PH, et al.  Optimizing insulin secretagogue therapy in patients with type 2 diabetes. Diab. Care. 2002;25:342–346
  16. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM. Glycated haemoglobin: methodologies and clinical applications. Clin. Chem. 1986;32:B64–B70
  17. Marbury T, Huang W-C, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diab. Res. Clin. Pract. 1999;43:155–166
  18. American Diabetes Association Consensus Statement, Post-prandial blood glucose, Diab. Care 24 (2001) 775–778.

PII: S0168-8227(03)00253-5

doi: 10.1016/j.diabres.2003.10.006

Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 33-40 , April 2004

Article Tools